Study: USPSTF Mammogram Recs Based on Inaccurate Information
The number of women who must undergo mammograms to prevent one breast cancer death is lower than stated by the U.S. Preventative Services Task Force, researchers found.
The number of women who must undergo mammograms in order to prevent one breast cancer death is lower than stated by the U.S. Preventative Services Task Force (USPSTF), according to a study published in the March issue of the American Journal of Roentgenology.
The USPSTF used incorrect numbers in their calculations, said researchers, which were then used in 2009 to recommend that women aged 40 to 49 years not receive annual mammograms. It was claimed that the potential harm from the tests outweighed potential benefits. The new recommendation suggested that women consult with their physician regarding when screening should be done.
The erroneous calculation was made on the number of women who were invited to undergo a screening mammography, not the actual number of women who went through with the procedure, according to researchers R. Edward Hendrick and Mark A. Helvie.
The modeling used by the USPSTF showed that 746 women needed to be screened to save one life. When the number of women who underwent the mammogram was used instead of the total number, researchers found that only 84 women needed to be screened annually, between the ages of 40 and 84 years, to save one life.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
